Premium
Predictors of therapeutic failure among patients with acute brucellosis treated by dual therapy with doxycycline‐rifampin
Author(s) -
Alsayed Hasanain Ahmad Farooq,
ElMasry Muhammad Abbas,
Zayed Ali AbdelAzeem Hasan,
Nafee Amany Mohamed Adawi,
Attia Rasha AbdelMonem Hassan,
AbdelAal Sherif Mohamed
Publication year - 2019
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/tmi.13179
Subject(s) - medicine , doxycycline , brucellosis , therapeutic effect , gastroenterology , adverse effect , tuberculosis , ascariasis , population , surgery , immunology , antibiotics , pathology , microbiology and biotechnology , biology , environmental health , helminths
Abstract Objective To determine the frequency of therapeutic failure among patients with acute and subacute brucellosis and to explore the predictors of failure. Methods The study included 213 consecutive, naïve patients with acute and subacute brucellosis. All participants underwent clinical evaluation, chest radiography, stool microscopic examination and interferon‐gamma release assay. Patients received the WHO‐recommended therapy of doxycycline 200 mg/day and rifampin 900 mg/day, for 6 weeks. Results Mean age of the study population was 39.8 ± 12.2 years; 64.8% of them were males. The therapeutic failure rate was 16.4%. Adverse effects were reported by 13.1%. Multivariate analysis of factors associated with therapeutic failure revealed latent tuberculosis infection (LTBI) (OR 3.1, 95% CI, 1.9–24.6, P : 0.009), ascariasis (OR 2.6, 95% CI 1.5–17.9, P : 0.012), and the use of acid suppressive therapy (OR 2.1, 95% CI 1.2–19.5, P : 0.037) as the predictors of therapeutic failure. Conclusions The prevalence of therapeutic failure among the Egyptian patients with acute/subacute brucellosis is increasing. Predictors of therapeutic failure are LTBI, ascariasis, and the use of acid suppressive therapy.